Definium to present phase 3 anxiety disorder trial results Monday
Definium Therapeutics, Inc. (NASDAQ:DFTX) will unveil the results of its Phase 3 Panorama study on Monday at 8:00 a.m. EDT through an online presentation. The study examines the efficacy and safety of DT120 Orally Disintegrating Tablet (DT120 ODT) in treating generalized anxiety disorder among adults. Conducted at 32 centers, the trial involved 245 participants aged 18-74 years who were randomly assigned to receive either a 100 µg, 50 µg, or placebo dose of DT120 ODT.
The primary objective is to measure the change in Hamilton Anxiety Rating Scale scores from baseline at Week 12, while secondary endpoints include changes in Clinical Global Impression-Severity scores at Week 12, HAM-A scores at Week 1, and CGI-S scores on Day 2. Definium Therapeutics, a late-stage biopharmaceutical company focused on psychiatric and neurological disorders, is headquartered in New York.
A replay of the webcast will be accessible on their investor relations website for at least 30 days.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
